ESMO 2023: Highlights on selpercatinib in RET fusion-positive NSCLC: The LIBRETTO-431 study
Share.
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.